Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Q Shao, S Wang, H Jiang & L Liu. (2021) Efficacy and safety of iguratimod on patients with primary Sjögren’s syndrome: a randomized, placebo-controlled clinical trial. Scandinavian Journal of Rheumatology 50:2, pages 143-152.
Read now
Read now
Kyosuke Hattori, Yuji Hirano, Yasuhide Kanayama, Yosuke Hattori, Takefumi Kato, Nobunori Takahashi, Naoki Ishiguro & Toshihisa Kojima. (2021) Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors. Modern Rheumatology 31:1, pages 80-87.
Read now
Read now
Naoki Ishiguro, Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2020) Investigation of the predictors of the response to Iguratimod therapy: A post-hoc analysis of post-marketing surveillance study. Modern Rheumatology 30:4, pages 626-632.
Read now
Read now
Takahito Suto, Yukio Yonemoto, Koichi Okamura, Hideo Sakane, Kimihiko Takeuchi, Yasuyuki Tamura, Tetsuya Kaneko, Keio Ayabe & Hirotaka Chikuda. (2019) The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. Modern Rheumatology 29:5, pages 775-781.
Read now
Read now
Koichiro Ishikawa & Junichiro Ishikawa. (2019) Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients. Modern Rheumatology 29:3, pages 418-429.
Read now
Read now
Hideto Kameda, Takao Fujii, Ayako Nakajima, Ryuji Koike, Akira Sagawa, Katsuaki Kanbe, Tetsuya Tomita, Masayoshi Harigai & Yasuo Suzuki. (2019) Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Modern Rheumatology 29:1, pages 31-40.
Read now
Read now
Yuki Arita, Hiroaki Taguchi, Mari Kobayashi, Toshihiro Tono, Yasuo Ohsone & Yutaka Okano. (2018) pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept. Modern Rheumatology 28:6, pages 1041-1043.
Read now
Read now
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi & Shigeki Makino. (2018) Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Modern Rheumatology 28:2, pages 227-234.
Read now
Read now
Ryosuke Kamei, Masanori Kono, Yukiko Iwasaki, Hirofumi Shoda, Kanae Kubo, Keishi Fujio & Kazuhiko Yamamoto. (2017) Iguratimod-induced acute interstitial pneumonia with hypogammaglobulinemia in a rheumatoid arthritis patient. Modern Rheumatology Case Reports 1:2, pages 54-59.
Read now
Read now
Yutaka Yoshioka, Nobunori Takahashi, Atsushi Kaneko, Yuji Hirano, Yasuhide Kanayama, Hiroyasu Kanda, Hideki Takagi, Takayasu Ito, Takefumi Kato, Kiwamu Saito, Koji Funahashi, Shuji Asai, Toki Takemoto, Kenya Terabe, Nobuyuki Asai, Naoki Ishiguro & Toshihisa Kojima. (2016) Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod. Modern Rheumatology 26:2, pages 169-174.
Read now
Read now
Koichi Okamura, Yukio Yonemoto, Takahito Suto, Chisa Okura & Kenji Takagishi. (2015) Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis. Modern Rheumatology 25:4, pages 534-539.
Read now
Read now
Keiichi Tanaka, Tomonobu Yamaguchi & Masako Hara. (2015) Iguratimod for the treatment of rheumatoid arthritis in Japan. Expert Review of Clinical Immunology 11:5, pages 565-573.
Read now
Read now
Koichi Okamura, Yukio Yonemoto, Chisa Okura, Tsutomu Kobayashi & Kenji Takagishi. (2015) Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Modern Rheumatology 25:2, pages 235-240.
Read now
Read now
Articles from other publishers (31)
Liuting Zeng, Qi He, Ying Deng, Yuwei Li, Junpeng Chen, Kailin Yang, Yanfang Luo, Anqi Ge, Xiaofei Zhu, Zhiyong Long & Lingyun Sun. (2023) Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials. Frontiers in Pharmacology 14.
Crossref
Crossref
Xiaoli Chu, Bingzhen Sun, Xiaodong Chu, Yan Zhang, Qingchun Huang & Jianxiong Cai. (2022) A quantitative and qualitative hybrid attributes based imbalanced group conflict analysis method and its application to evaluation of clinical therapeutic effect. Artificial Intelligence Review 56:6, pages 5773-5798.
Crossref
Crossref
Qingran Yan, Bei Liu, Jieying Wang, Hanlin Yin, Qianqian Li & Liangjing Lu. (2023) Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer. Frontiers in Medicine 10.
Crossref
Crossref
Tianqi Zhang, Qin Shu, Huaijun Zhu, Min Wang, Na Yang, Huayong Zhang & Weihong Ge. (2023) Serum proteomics analysis of biomarkers for evaluating clinical response to MTX/IGU therapy in early rheumatoid arthritis. Molecular Immunology 153, pages 119-125.
Crossref
Crossref
Zhou Hang, Jintao Wei, Ming Zheng, Zeping Gui, Hao Chen, Li Sun, Shuang Fei, Zhijian Han, Jun Tao, Zijie Wang, Ruoyun Tan & Min Gu. (2022) Iguratimod Attenuates Macrophage Polarization and Antibody-Mediated Rejection After Renal Transplant by Regulating KLF4. Frontiers in Pharmacology 13.
Crossref
Crossref
Liuting Zeng, Ganpeng Yu, Kailin Yang, Wensa Hao & Hua Chen. (2022) The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial. Frontiers in Pharmacology 12.
Crossref
Crossref
George Robinson, Ines Pineda-Torra, Coziana Ciurtin & Elizabeth C. Jury. (2022) Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. Journal of Clinical Investigation 132:2.
Crossref
Crossref
Chao-Jun Hu, Li Zhang, Shuang Zhou, Nan Jiang, Jiu-Liang Zhao, Qian Wang, Xin-Ping Tian & Xiao-Feng Zeng. (2021) Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs. Journal of Orthopaedic Surgery and Research 16:1.
Crossref
Crossref
L.-J. Chen, Y.-J. Zhou, Z.-H. Wen, F. Tian & J.-Y. Li. (2020) Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritisWirksamkeit und Sicherheit von Iguratimod in Kombination mit Methotrexat vs. Methotrexat allein bei rheumatoider Arthritis. Zeitschrift für Rheumatologie 80:5, pages 432-446.
Crossref
Crossref
Yuji Nozaki. (2021) Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World. Life 11:5, pages 457.
Crossref
Crossref
Rong Mu, Chun Li, Xiaomei Li, Yao Ke, Ling Zhao, Lin Chen, Rui Wu, Zhenbiao Wu, Xiaoxia Zuo, Yanli Xie, Jinwei Chen, Wei Wei, Yi Liu, Zhijun Li, Lie Dai, Lingyun Sun, Xiangyuan Liu & Zhanguo Li. (2021) Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. The Lancet Regional Health - Western Pacific 10, pages 100128.
Crossref
Crossref
Xinping Tian, Qian Wang, Mengtao Li, Yan Zhao, Zhiyi Zhang, Cibo Huang, Yi Liu, Huji Xu, Yaolong Chen, Lijun Wu, Yin Su, Weiguo Xiao, Miaojia Zhang, Dongbao Zhao, Linyun Sun, Xiaoxia Zuo, Junqiang Lei, Xiaofeng Li & Xiaofeng Zeng. (2021) 2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. Rheumatology and Immunology Research 2:1, pages 1-14.
Crossref
Crossref
Satoshi Mizutani, Hitoshi Kodera, Yoshiko Sato, Toshihiro Nanki, Shunji Yoshida & Hidekata Yasuoka. (2020) Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis. Clinical Rheumatology 40:1, pages 123-132.
Crossref
Crossref
Asuka Inoue, Yuji Nozaki, Yasuaki Hirooka, Koji Kinoshita, Yasutaka Chiba, Masanori Funauchi & Itaru Matsumura. (2020) The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care. Life 10:11, pages 261.
Crossref
Crossref
Adam Kilian, Yu Pei Chock, Irvin J. Huang, Elizabeth R. Graef, Laura A. Upton, Aneka Khilnani, Sonia D. Silinsky Krupnikova, Ibrahim Almaghlouth, Laura C. Cappelli, Ruth Fernandez-Ruiz, Brittany A. Frankel, Jourdan Frankovich, Carly Harrison, Bharat Kumar, Kanika Monga, Jorge A. Rosario Vega, Namrata Singh, Jeffrey A. Sparks, Elaine Sullo, Kristen J. Young, Ali Duarte-Garcia, Michael Putman, Sindhu Johnson, Rebecca Grainger, Zachary S. Wallace, Jean W. Liew & Aruni Jayatilleke. (2020) Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Seminars in Arthritis and Rheumatism 50:5, pages 1191-1201.
Crossref
Crossref
Magdalena Massalska, Wlodzimierz Maslinski & Marzena Ciechomska. (2020) Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. Cells 9:8, pages 1876.
Crossref
Crossref
Sisi Xie, Shu Li, Jing Tian & Fen Li. (2020) Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape. Frontiers in Pharmacology 11.
Crossref
Crossref
Sisi Xie, Shu Li, Jing Tian & Fen Li. (2020) Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape. Frontiers in Pharmacology 11.
Crossref
Crossref
Huihui Jiang, Hongyan Gao, Qin Wang, Miao Wang & Bin Wu. (2020) Molecular mechanisms and clinical application of Iguratimod: A review. Biomedicine & Pharmacotherapy 122, pages 109704.
Crossref
Crossref
Yanying Liu, Yuxin Zhang, Wenjie Bian, Jiangnan Fu, Xing Sun, Da Chen, Jiali Chen, Xiaozhen Zhao, Yingni Li, Wen Zhang & Zhanguo Li. (2019) Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease. Clinical Rheumatology 39:2, pages 491-497.
Crossref
Crossref
Yan Ye, Mei Liu, Longhai Tang, Fang Du, Yuanhua Liu, Pei Hao, Qiong Fu, Qiang Guo, Qingran Yan, Xiaoming Zhang & Chunde Bao. (2019) Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. Arthritis Research & Therapy 21:1.
Crossref
Crossref
Jie Li, Jun Bao, Jian Zeng, Aizhu Yan, Chunqiu Zhao & Qiang Shu. (2019) Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology. Bone Research 7:1.
Crossref
Crossref
Muhammad Usman, Zhu Zhen-Han, Chang Ze-Na, Han Jun-Ping, Qian Wen, Yang Chang-Qing, Nishikawa Miyu & Sakaki Toshiyuki. (2019) Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells. Brazilian Journal of Pharmaceutical Sciences 55.
Crossref
Crossref
Ying Xia, Shunbo Zhao, Meng Gong & Li Ding. (2018) A rapid and sensitive LC-MS/MS method for analysis of iguratimod in human plasma: Application to a pharmacokinetic study in Chinese healthy volunteers. Biomedical Chromatography 32:9, pages e4277.
Crossref
Crossref
Lisa Caulley, Alexandra Quimby, Jacob Karsh, Azin Ahrari, Darren Tse & Georgios Kontorinis. (2018) Autoimmune arthritis in Ménière’s disease: A systematic review of the literature. Seminars in Arthritis and Rheumatism 48:1, pages 141-147.
Crossref
Crossref
Yue Sun, Ying-Xing Wu, Peng Zhang, Guang Peng & Shi-Ying Yu. (2017) Anti-rheumatic drug iguratimod protects against cancer-induced bone pain and bone destruction in a rat model. Oncology Letters 13:6, pages 4849-4856.
Crossref
Crossref
Z. Xia, J. Lyu, N. Hou, L. Song, X. Li & H. Liu. (2015) Iguratimod in combination with methotrexate in active rheumatoid arthritisIguratimod in Kombination mit Methotrexat bei aktiver rheumatoider Arthritis. Zeitschrift für Rheumatologie 75:8, pages 828-833.
Crossref
Crossref
Xin-Wang Duan, Xiu-Ling Zhang, Shao-Yuan Mao, Jing-Jing Shang & Xiao-Dong Shi. (2015) Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clinical Rheumatology 34:9, pages 1513-1519.
Crossref
Crossref
Tatsuya Koike & Kentaro Inui. (2015) How can the treatment of rheumatoid arthritis be improved in Japan?. International Journal of Clinical Rheumatology 10:4, pages 235-244.
Crossref
Crossref
Erik Lubberts. (2015) The IL-23–IL-17 axis in inflammatory arthritis. Nature Reviews Rheumatology 11:7, pages 415-429.
Crossref
Crossref
Satoshi Yamaori, Ken Takami, Ayaka Shiozawa, Kanako Sakuyama, Naoki Matsuzawa & Shigeru Ohmori. (2015) <i>In Vitro</i> Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 38:3, pages 441-447.
Crossref
Crossref